2. UroToday Home
  3. Video Lectures

mHSPC Videos

The Combination of Enzalutamide Plus Talazoparib for Patients With Castration-Sensitive Metastatic Prostate Cancer With HRR Gene Alterations (TALAPRO-3) - Neeraj Agarwal
March 4, 2023
Details
mHSPC Network Meta-Analysis on the Use of Intensified Treatments - Fred Saad
February 3, 2023
Details
Treatment Intensification in Metastatic Castrate-Sensitive Prostate Cancer - Zachary Klaassen
February 2, 2023
Details
Considerations for Integrating Triplet Therapy Into Clinical Practice - Evan Yu
January 31, 2023
Details
Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer, Advances and Barriers – Cora Sternberg
January 23, 2023
Details
mCSPC Couplet vs Triplet Therapy LUGPA 2022 Presentation - Alicia Morgans
December 15, 2022
Details
Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay
December 5, 2022
Details
The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz
November 16, 2022
Details
8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam
November 11, 2022
Details
The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore
October 17, 2022
Details
APCCC 2022: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer - Evan Yu
October 16, 2022
Details
(AFT19) PRESTO Study Prolonging Biochemical Progression-Free Survival in Biochemically Relapsed Prostate Cancer with Intensification of ADT - Charles Ryan
October 12, 2022
Details
Prolonging PSA Progression-Free Survival with Intensification of ADT, the PRESTO Study (AFT19) - Rahul Aggarwal
October 12, 2022
Details
Treatment of Vulnerable/Frail Patients with mHSPC APCCC 2022 Presentation - Alicia Morgans
September 21, 2022
Details
Optimal Treatment for mHSPC from a Health Economics Standpoint APCCC 2022 Presentation - Caroline Clarke
September 21, 2022
Details
Can Biology Help Inform Treatment Decisions In the Management of mHSPC? APCCC 2022 Presentation - Gert Attard
September 11, 2022
Details
Treatment De-escalation Strategies in mHSPC APCCC 2022 Presentation - Bertrand Tombal
August 23, 2022
Details
Treatment Intensification Strategies in mHSPC: Triplets and More APCCC 2022 Presentation - Christopher Sweeney
August 23, 2022
Details
When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Treat like Low-Volume APCCC 2022 Presentation - Karim Fizazi
August 22, 2022
Details
When Low-Volume on Conventional Imaging Goes into High-Volume on Next-Generation Imaging in mHSPC - How Frequent Is This Situation? APCCC 2022 Presentation - Michael Hofman
August 22, 2022
Details
The Uptake of New Treatment Options for mHSPC in Real Life -- Education, Access, Use, and Diversity APCCC 2022 Presentation - Andrew Armstrong
August 22, 2022
Details
A Urologist's Perspective On Treatment with Darolutamide in the Metastatic Hormone Sensitive Patient - Neal Shore
August 8, 2022
Details
Outcomes of the ARASENS Trial by Metastatic Subtype - Bertrand Tombal
August 8, 2022
Details
Darolutamide Approved for Patients with mHSPC - Charles Ryan
August 5, 2022
Details
De-escalation Treatment Strategies in Metastatic Hormone-Sensitive Prostate Cancer - Bertrand Tombal
June 24, 2022
Details
When Low-Volume on Conventional Imaging Goes Into High-Volume on Next-Generation Imaging in mHSPC - Karim Fizazi
June 19, 2022
Details
The Importance of Multidisciplinary Collaboration in Urology Clinics - Neal Shore
June 8, 2022
Details
Real-World Treatment Trends in Metastatic Castration-Sensitive Prostate Cancer - Pedro Barata
March 25, 2022
Details
Practice Changing Data from ARASENS - Statistically Significant Overall Survival - Fred Saad, Bertrand Tombal, and Neal Shore
March 23, 2022
Details
ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Journal Club - Christopher Wallis & Zachary Klaassen
March 21, 2022
Details
Darolutamide and Survival in Metastatic Hormone-Sensitive Prostate Cancer - ARASENS Trial - Karim Fizazi
February 24, 2022
Details
Trials and Tribulations in the Management of Metastatic Hormone-Sensitive Prostate Cancer - Heather Payne
December 2, 2021
Details
The Efficacy of Enzalutamide + ADT vs Placebo + ADT in Patients Who Received Prior Antiandrogen Therapy in the ARCHES Study – Neal Shore
September 27, 2021
Details
Overall Survival Results of PEACE-1 a Phase 3 Trial in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC) – Karim Fizazi
September 19, 2021
Details
Radiographic Progression Free Survival in Metastatic Hormone Sensitive Prostate Cancer, The ARCHES Study - Daniel Petrylak
July 18, 2021
Details
Intensification of Hormonal Therapy for Men With Metachronous Metastatic Hormone-Sensitive Disease – Chris Sweeney
June 21, 2021
Details
Selection of Androgen Deprivation Therapy for Use in Advanced Prostate Cancer - Bertrand Tombal
May 13, 2021
Details
Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer - The TITAN Study - Neeraj Agarwal
April 30, 2021
Details
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer - Matthew Deek & Phuoc Tran
February 14, 2021
Details
Standard of Care in the Treatment of Metastatic Hormone-Sensitive Prostate Cancer - Michael Morris & Christopher Sweeney
September 13, 2020
Details
Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer - Evan Yu
June 26, 2020
Details
Quality of Life in the Treatment of mHSPC: The STAMPEDE Trial - Hannah Rush
March 3, 2020
Details
Categorizing Patients with Hormone-Sensitive Prostate Cancer - Christopher Sweeney
February 2, 2020
Details
Systemic Therapies in High Volume & Low Volume Disease in the Treatment of Metastatic Hormone Sensitive Prostate Cancer from the STAMPEDE Trial- Nick James
January 1, 2020
Details
The Biology of Prostate Cancer - Kenneth Pienta
November 26, 2019
Details
Prolonging Time to Metastatic Disease, The SPARTAN Study - Matthew Smith
October 29, 2019
Details
Patient-reported Outcomes from TITAN: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer - Neeraj Agarwal
October 22, 2019
Details
Treating the Primary in High vs Low Volume Hormone Sensitive Disease - Interview Noel Clarke
October 4, 2019
Details
First - Line mCRPC After ADT + Docetaxel or AR Pathway Inhibitor Presentation - Mary-Ellen Taplin
September 24, 2019
Details
Optimal Glucocorticoid Regimen with Abiraterone Acetate Presentation - Gert Attard
September 16, 2019
Details
Follow Up of ADT Alone vs. ADT "Plus" Presentation - William Oh
September 10, 2019
Details
Addition of AR Pathway Inhibitors vs. Docetaxel: Statisticians' Perspective Presentation - Matthew R Sydes
September 10, 2019
Details
The Upheaval in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Chris Sweeney & Mary-Ellen Taplin
August 19, 2019
Details
TITAN, TALAPRO-2 And Ongoing Clinical Trials for Prostate Cancer - Neeraj Agarwal
August 18, 2019
Details
Clinical Implications of TITAN in mHSPC - Kim Chi and Michael Morris
June 22, 2019
Details
Combinatorial Treatment Strategies in mHSPC - Mary-Ellen Taplin
June 5, 2019
Details
Treatment Approaches in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)- Alicia Morgans
May 26, 2019
Details
Contemporary Management of Hormone Sensitive Prostate Cancer - Alicia Morgans
April 9, 2019
Details
Patients' Quality of Life in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treatment Decisions - Alicia Morgans
June 16, 2019
Details
The Role of the Nurse Practitioner in the Treatment of mHSPC - Leanne Schimke
March 26, 2019
Details
Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans
January 31, 2019
Details
STAMPEDE Trial Updates in Prostate Cancer - Silke Gillessen
December 5, 2018
Details
A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney
November 29, 2018
Details
Radical Prostatectomy for Patients with Oligometastatic Prostate Cancer - Robert Hamilton
March 5, 2018
Details